Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Biofrontera Inc. (BFRI : NSDQ)
 
 • Company Description   
Biofrontera Inc. is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company's licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Biofrontera Inc. is based in WOBURN, MA.

Number of Employees: 69

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.80 Daily Weekly Monthly
20 Day Moving Average: 474,387 shares
Shares Outstanding: 17.10 (millions)
Market Capitalization: $47.89 (millions)
Beta:
52 Week High: $14.63
52 Week Low: $2.20
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -26.32% -17.01%
12 Week -5.41% 4.00%
Year To Date -62.77% -54.51%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
120 PRESIDENTIAL WAY SUITE 330
-
WOBURN,MA 01801
USA
ph: 781-245-1325
fax: -
us-ir@biofrontera.com http://www.biofrontera.us.com
 
 • General Corporate Information   
Officers
Erica Monaco - Chief Executive Officer
Hermann Lubbert - Chairman of the Board of Directors
John J. Borer - Director
Loretta M. Wedge - Director
Kevin D. Weber - Director

Peer Information
Biofrontera Inc. (CORR.)
Biofrontera Inc. (RSPI)
Biofrontera Inc. (CGXP)
Biofrontera Inc. (BGEN)
Biofrontera Inc. (GTBP)
Biofrontera Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09077D100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/12/22
Share - Related Items
Shares Outstanding: 17.10
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $47.89 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.72 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.75
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 80.95%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 6.36%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - 3.44
12/31/21 - 3.36
09/30/21 - 0.90
Quick Ratio
03/31/22 - -
12/31/21 - 3.03
09/30/21 - 0.42
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -156.25
09/30/21 - -
Book Value
03/31/22 - 1.02
12/31/21 - 0.66
09/30/21 - -1.50
Inventory Turnover
03/31/22 - -
12/31/21 - 2.57
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - -
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - -
 

Powered by Zacks Investment Research ©